XML 1057 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 185 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Dec. 31, 2011
Operating activities:        
Net loss $ (15,243) $ (16,021) $ (19,570) $ (253,549)
Adjustments to reconcile net loss to net cash used in operating activities:        
Accretion of interest on notes payable, net of amortization of debt premium     2 100
Amortization of investment premiums, net     20 (2,297)
Change in valuation of derivative 20     328
Change in valuation of warrants (629) 338 299 (6,699)
Warrant re-pricing     44 44
Depreciation 241 457 668 12,555
Amortization of intangible assets       886
Fixed asset impairment     221 221
Unrealized foreign exchange (gains) losses       7,747
Deferred revenue       (98)
Compensation for warrants issued to non-employees       1,215
Shares issued for IP rights       446
Loss (gain) on disposal of property, plant and equipment 1 (13) 83 100
Goodwill and intangibles impairment       7,934
Stock-based compensation 882 1,746 810 19,023
Provision for restructuring       1,779
Amortization of issuance costs of Preferred Ordinary 'C' shares       2,517
Changes in operating assets and liabilities:        
Prepaid expenses and other assets 174 516 1,716 (58)
Accounts payable and other current liabilities 577 (3,067) 821 (5,313)
Net cash used in operating activities (13,977) (16,044) (14,886) (213,119)
Investing activities:        
Purchase of ALIGN       (3,763)
Purchase of property, plant and equipment (6) (8) (15) (8,837)
Proceeds from sale of property, plant and equipment 5 41 91 163
Purchase of short-term investments on deposit, net of maturities       (156,657)
Cash proceeds from redemption of short term securities     1,483 162,729
Net cash provided by (used in) investing activities (1) 33 1,559 (6,365)
Financing activities:        
Payments of capital lease obligations       (3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs   30,820   121,678
Proceeds from issuance of common stock and warrants, net of issuance costs 9,267 2,576 3,845 91,671
Proceeds from the exercise of stock options and warrants, net of issuance costs 3   7 173
Payment of preferred stock dividend (364)   (307) (1,898)
Repayment of government loan       (455)
Government loan received       414
Loan received from Cyclacel Group plc       9,103
Proceeds of committable loan notes issued from shareholders       8,883
Loans received from shareholders       1,645
Cash and cash equivalents assumed on stock purchase of Xcyte       17,915
Costs associated with stock purchase       (1,951)
Net cash provided by financing activities 8,906 33,396 3,545 243,459
Effect of exchange rate changes on cash and cash equivalents 26 617 (2,945) 474
Net (decrease) increase in cash and cash equivalents (5,046) 18,002 (12,727) 24,449
Cash and cash equivalents, beginning of period 29,495 11,493 24,220  
Cash and cash equivalents, end of period 24,449 29,495 11,493 24,449
Cash received during the period for:        
Interest 31 11 59 11,746
Taxes 685 1,082 1,523 18,207
Cash paid during the period for:        
Interest   (155) (78) (1,914)
Schedule of non-cash transactions:        
Acquisitions of equipment purchased through capital leases       3,470
Issuance of common shares in connection with license agreements       592
Issuance of Ordinary shares on conversion of bridging loan       1,638
Issuance of Preferred Ordinary 'C' shares on conversion of secured convertible loan notes and accrued interest       8,893
Issuance of Ordinary shares in lieu of cash bonus       164
Issuance of other long term payable on ALIGN acquisition       $ 1,122